News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
232,007 Results
Type
Article (5090)
Company Profile (24)
Press Release (226893)
Multimedia
Podcasts (2)
Webinars (4)
Section
Business (82245)
Career Advice (463)
Deals (15054)
Drug Delivery (8)
Drug Development (19073)
Employer Resources (30)
FDA (3682)
Job Trends (3909)
News (120177)
Policy (7512)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (293)
Accelerated approval (6)
Adcomms (4)
Allergies (14)
Alliances (14808)
ALS (38)
Alzheimer's disease (294)
Antibody-drug conjugate (ADC) (40)
Approvals (3782)
Artificial intelligence (80)
Autoimmune disease (27)
Automation (5)
Bankruptcy (97)
Best Places to Work (2865)
Biosimilars (32)
Biotechnology (23)
Bladder cancer (34)
Brain cancer (7)
Breast cancer (101)
Cancer (886)
Cardiovascular disease (61)
Career advice (395)
Career pathing (3)
CAR-T (64)
CDC (2)
Cell therapy (166)
Cervical cancer (5)
Clinical research (16682)
Collaboration (353)
Compensation (371)
Complete response letters (8)
COVID-19 (311)
CRISPR (13)
C-suite (338)
Cystic fibrosis (28)
Data (1325)
Denatured (1)
Depression (21)
Diabetes (78)
Diagnostics (2114)
Digital health (7)
Diversity (1)
Diversity, equity & inclusion (13)
Drug discovery (31)
Drug pricing (14)
Drug shortages (2)
Duchenne muscular dystrophy (35)
Earnings (42737)
Editorial (5)
Employer branding (6)
Employer resources (32)
Events (39136)
Executive appointments (424)
FDA (4420)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (340)
Gene editing (24)
Generative AI (5)
Gene therapy (102)
GLP-1 (144)
Government (422)
Guidances (197)
Healthcare (5045)
HIV (10)
Huntington's disease (5)
IgA nephropathy (11)
Immunology and inflammation (39)
Immuno-oncology (7)
Indications (16)
Infectious disease (337)
Inflammatory bowel disease (36)
Inflation Reduction Act (3)
Influenza (6)
Intellectual property (32)
Interviews (53)
IPO (7880)
IRA (3)
Job creations (1122)
Job search strategy (361)
JPM (4)
Kidney cancer (10)
Labor market (10)
Layoffs (106)
Leadership (5)
Legal (2337)
Liver cancer (21)
Longevity (2)
Lung cancer (92)
Lymphoma (70)
Machine learning (3)
Management (10)
Manufacturing (139)
MASH (50)
Medical device (3918)
Medtech (3928)
Mergers & acquisitions (7579)
Metabolic disorders (214)
Multiple sclerosis (18)
NASH (6)
Neurodegenerative disease (54)
Neuropsychiatric disorders (12)
Neuroscience (539)
NextGen: Class of 2026 (1674)
Non-profit (730)
Now hiring (5)
Obesity (84)
Opinion (32)
Ovarian cancer (26)
Pain (26)
Pancreatic cancer (38)
Parkinson's disease (50)
Partnered (6)
Patents (51)
Patient recruitment (96)
Peanut (6)
People (25216)
Pharmaceutical (7)
Pharmacy benefit managers (2)
Phase 1 (4994)
Phase 2 (7225)
Phase 3 (5788)
Pipeline (1962)
Policy (17)
Postmarket research (625)
Preclinical (1946)
Press Release (66)
Prostate cancer (57)
Psychedelics (3)
Radiopharmaceuticals (109)
Rare diseases (179)
Real estate (1886)
Recruiting (8)
Regulatory (5536)
Reports (17)
Research institute (308)
Resumes & cover letters (69)
Rett syndrome (19)
RNA editing (1)
RSV (2)
Schizophrenia (49)
Series A (53)
Series B (54)
Sickle cell disease (10)
Special edition (1)
Spinal muscular atrophy (33)
Sponsored (5)
Startups (1017)
Stomach cancer (1)
Supply chain (13)
Tariffs (7)
The Weekly (1)
Vaccines (80)
Venture capital (9)
Weight loss (29)
Women's health (6)
Date
Last 7 days (146)
Last 30 days (563)
Last 365 days (8886)
2026 (784)
2025 (9036)
2024 (11031)
2023 (13195)
2022 (18660)
2021 (19678)
2020 (18238)
2019 (13205)
2018 (10206)
2017 (10001)
2016 (9156)
2015 (12118)
2014 (9587)
2013 (7707)
2012 (8329)
2011 (8796)
2010 (8634)
Location
Africa (186)
Alabama (19)
Alaska (2)
Arizona (74)
Arkansas (1)
Asia (11782)
Australia (1690)
California (3541)
Canada (1138)
China (167)
Colorado (143)
Connecticut (162)
Delaware (70)
Europe (25488)
Florida (541)
Georgia (67)
Idaho (24)
Illinois (161)
India (14)
Indiana (105)
Iowa (9)
Japan (164)
Kansas (36)
Kentucky (17)
Louisiana (8)
Maine (51)
Maryland (352)
Massachusetts (2803)
Michigan (104)
Minnesota (201)
Mississippi (1)
Missouri (31)
Montana (17)
Nebraska (12)
Nevada (46)
New Hampshire (16)
New Jersey (1018)
New Mexico (5)
New York (814)
North Carolina (479)
North Dakota (4)
Northern California (1854)
Ohio (116)
Oklahoma (5)
Oregon (6)
Pennsylvania (597)
Puerto Rico (1)
Rhode Island (19)
South America (279)
South Carolina (17)
Southern California (1304)
Tennessee (61)
Texas (480)
United States (12328)
Utah (111)
Virginia (84)
Washington D.C. (17)
Washington State (297)
West Virginia (2)
Wisconsin (57)
Wyoming (1)
232,007 Results for "immunobiochem corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
ImmunoBiochem Announces Multi-Target License and Option Agreement with ImmunoGen to Develop Next-Generation Antibody-Drug Conjugates
ImmunoBiochem Corporation announced a multi-target license and option agreement with ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates, to advance novel, first-in-class ADCs.
July 24, 2023
·
4 min read
Genetown
ImmunoGen Announces Multi-Target License and Option Agreement with ImmunoBiochem to Develop Next-Generation Antibody-Drug Conjugates
ImmunoGen, Inc. announced a multi-target license and option agreement to research novel, first-in-class ADCs with ImmunoBiochem Corporation, a privately-held biopharmaceutical company focused on the discovery of unique tumor targets and development of novel biological therapeutics.
July 24, 2023
·
5 min read
Business
ImmunoGen Inks Cancer ADC Partnership with ImmunoBiochem
The license and option deal, for an undisclosed amount, seeks to develop potentially first-in-class antibody-drug conjugate candidates against different oncology targets.
July 25, 2023
·
2 min read
·
Tristan Manalac
Press Releases
Lyra Therapeutics Provides Corporate Update
January 12, 2026
·
4 min read
Press Releases
Skye Provides 2026 Corporate Outlook
January 12, 2026
·
8 min read
Press Releases
Kiniksa Pharmaceuticals Provides Corporate Update
January 12, 2026
·
11 min read
Press Releases
Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook
January 13, 2026
·
7 min read
Press Releases
Mereo BioPharma Provides Corporate Update
January 12, 2026
·
9 min read
Press Releases
Humanetics Corporation to Present at Upcoming February 2026 Investor Conference
February 3, 2026
·
1 min read
Press Releases
IO Biotech Provides Corporate Update - January 30, 2026
February 1, 2026
·
2 min read
1 of 23,201
Next
